# Psilera Advances NIH-Funded AUD Research

On October 8, 2026, Psilera announced it is starting Phase 2 of an NIH-supported Small Business Innovation Research (SBIR) project studying non-hallucinogenic psilocybin derivatives for alcohol use disorder. The National Institute on Alcohol Abuse and Alcoholism funds the research under award 4R44AA031925-02; the award amount was not disclosed. Psilera expects to advance preclinical work before an anticipated Phase 1a clinical trial in 2027. The announcement concerns progress under an existing grant, not a newly open solicitation or procurement opportunity.

- For procurement and grants professionals, the announcement is an example of an SBIR-funded project advancing into a later research phase; it does not provide a new bid or application window.
- Companies evaluating the opportunity should distinguish this existing award from available funding: no new solicitation, award value, or application deadline is identified.
- The work is relevant to stakeholders in biomedical research and alcohol-use-disorder treatment development, particularly organizations involved in preclinical research and potential clinical translation.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** October 08, 2026

### Government Entities
- National Institutes of Health (NIH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)

### Vendors
- Psilera, Inc. (awardee)

### Key Quotes
> Along with our collaborator, Dr. Danielle Gulick at the University of South Florida, we continue to see promising results in reducing alcohol consumption in vivo.
> — Jackie von Salm, Chief Scientific Officer at Psilera

### Sources
- [Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder | Morningstar](https://www.morningstar.com/news/pr-newswire/20261008fl66116/psilera-greenlit-to-initiate-phase-2-of-nih-grant-for-alcohol-use-disorder) - Morningstar